

"Express Mail" Label No. EV 782 173 474 US

Date of Deposit: December 15 2005

PATENT
Attorney Docket No.: 15270J-004743US
Client Reference No.: 209US-CIP5C3

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office Box address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By:

Susan J. Johnson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/724,319

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

12/21/2005 DTESSEM1 00000015 201430 09724319

02 FC:1806 180.00 DA

Examiner: Lyles

Art Unit: 1649

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of non U.S. Patent references 580-642 can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). Copies of references 648-655, 662-666 and 676-678 are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
10/934,609 filed 09/02/04 issued as U.S. 6,946,135 on 09/20/2005;
10/933,559 filed 09/02/04 issue fee paid 01/24/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04 issue fee paid 01/24/05;
10/815,404 filed 03/31/04 issue fee paid 11/12/04;
10/884,892 filed 07/01/04 issued as U.S. 6,962,707 on 11/08/05
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;

10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;
10/923,469 filed 08/20/04;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00 issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,929 filed 11/28/00;
09/724,567 filed 11/28/00 issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00 issue fee paid 02/10/05;
09/585,656 filed 06/01/00;

09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);
09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);
issued as U.S. 6,913,745 on 07/05/05; and,
09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related
subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 02/27/04;
10/232,030 filed 08/30/02;
10/010,942 filed 12/06/01;
10/388,389 filed 03/12/03;
10/703,713 filed 11/07/03;
10/704,070 filed 11/07/03;
10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04.
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04.

Applicant further cites the following commonly owned abandoned applications
directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/251,892 filed 12/06/00;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99; and
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03;
60/444,150 filed 02/01/03; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining

papers from that source he or she is invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	7
-------	---	----	---

Complete if Known

Application Number	09/724,319
--------------------	------------

Filing Date	November 27, 2000
--------------------	-------------------

First Named Inventor	Schenk, D. B.
----------------------	---------------

Art Unit	1649
----------	------

Examiner Name	Lyles
---------------	-------

Attorney Docket Number	15270J-004743US
------------------------	-----------------

U.S. PATENT DOCUMENTS

		Document Number			
Examiner	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	658	6,905,686	06-14-2005	Schenk	
	659	6,890,535	05-10-2005	Schenk	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	583	2004/0265919 A1	12-30-2004	Vanderstichlele et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	642	5,702,906	12-30-1997	Rosenthal	
	675	6,710,226	02-23-2004	Schenk	
	643	5,693,762	12-02-1997	Queen et al.	
	644	5,618,920	04-08-1997	Robinson et al.	
	584	5,589,154	12-31-1996	Anderson	
	619	5,530,101	06-25-1996	Queen et al.	
	645	5,258,498	11-02-1993	Huston et al.	
	646	4,816,567	03-28-2989	Cabilly et al.	
	647	4,816,397	03-28-1989	Boss et al.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231
60659974

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	7
-------	---	----	---

Complete if Known

Application Number	09/724,319
--------------------	------------

Filing Date	November 27, 2000
--------------------	-------------------

First Named Inventor	Schenk, D. B.
----------------------	---------------

Art Unit	1649
----------	------

Examiner Name	Lyles
---------------	-------

Attorney Docket Number	15270J-004743US
------------------------	-----------------

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231
60659974



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk, D. B.		
		Art Unit	1649		
		Examiner Name	Lyles		
Sheet	3	of	7	Attorney Docket Number	15270J-004743US


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	591	CHROMY et al., "Self-assembly of Aβ(1-42) into globular neurotoxins," <i>Biochemistry</i> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid-β protein are generated from the β-amyloid precursor protein by different protease activities," <i>PNAS</i> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i> , 5:1055-1057 (2002).	
	594	DEMATTOIS et al., "Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <i>Science</i> , 295(5563):2264-2267 (2002).	
	595	DODART et al., "Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model," <i>Nat. Neurosci.</i> , 5(5):452-457 (2002).	
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <i>Lancet Neurol.</i> , 2(4):215-220 (2003).	
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <i>J. Neurochem.</i> , 76(1):173-181 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60659974

+



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

7

Complete if Known


Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Lyles
Attorney Docket Number	15270J-004743US

598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).
599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).
600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).
650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).
601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).
602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).
603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).
634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.
635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.
636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.
637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.
604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).
605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).
606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).
664	HARLOW et al., eds., <u>Antibodies: A Laboratory Manual</u> , pages 71-82 (1998).
607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60659974



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

7

Complete if Known


Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Lyles
Attorney Docket Number	15270J-004743US

662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Juman Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996).
608	IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).
609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).
640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <u>J. Neurosci. Res.</u> , 46:336-348 (1996).
628	KOFLER et al., "Mechanism of Allergic Cross-Reactions—III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <u>Mol. Immunology</u> , 29(2):161-166 (1992).
627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996).
651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , 166(3):1748-1754 (2001).
665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).
666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).
610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).
611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).
612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).
613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).
652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).
614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60659974



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk, D. B.		
		Art Unit	1649		
		Examiner Name	Lyles		
Sheet	6	of	7	Attorney Docket Number	15270J-004743US

615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <i>Biochemistry</i> , 38(12):3570-3578 (1999).	
654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>PNAS</i> , 85:3080-3084 (1998).	
653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).	
616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <i>Science</i> , 298(5597):1379 (2002).	
641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <i>J. Neurosci.</i> , 25(3):629-636 (2005).	
638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
655	RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982).	
617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	
629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <i>PNAS</i> , 96:2262-2267 (1999).	
618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <i>Science</i> , 298(5594):789-791 (2002).	
622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <i>J. Neurochem.</i> , 85(6):1581-1591 (2003).	
620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <i>J. Neural Transm. Suppl.</i> , 62:321-325 (2002).	
621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <i>DNA and Cell Biology</i> , 20(11):697-703 (2001).	
678	SOUDEK et al., "Overview of Alzheimer's disease," <i>Nurs. Clin. N. Am.</i> , 39:545-559 (2004).	
623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <i>Nature</i> , 416(6880):535-539 (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60659974

+



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449 PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 7

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Lyles
Attorney Docket Number	15270J-004743US

624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.
676	Webster's New World Dictionary, page 1387, therapeutic (1988).
625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).
580	ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers," <u>PNAS</u> , 93(9):4229-4334 (1996) abstract only.

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60659974